Polysomy is known to be an unfavourable prognostic marker and is associated with rapid progression of a cancer (Gschwendtner and Mairinger, 1999; Krause et al, 2003; Deliveliotis et al, 2005).
A high ability to mobilize CD34+ cells in peripheral blood (PB) was proved to be an unfavourable prognostic factor, independent of others such as class of cytogenetic risk or FAB morphotype [ 11- 13].
In our earlier studies, performed on a group of 60 patients with ductal breast cancer, postoperatively treated with tamoxifen, expression of metallothionein (MT), which is downregulated by ER was found to be an unfavourable prognostic factor (Surowiak et al, 2005b).
High expression of EGFR is considered to be an unfavourable prognostic factor in patients with a variety of tumours (Lieberman et al, 1985; Slamon et al, 1987; Neal et al, 1990), including renal cell carcinoma (RCC) (Uhlman et al, 1995; Yoshida et al, 1997).
Some markers may have applications in particular cases, e.g. overexpression of c-erbB2 is considered to be an unfavourable prognostic indicator for both node-negative and node-positive patients (Scorilas et al, 1995, 1999b), and HER-2/neu is useful for patient selection for Herceptin therapy (Hamilton and Piccart, 2000).
Surowiak P, Murawa D, Materna V, Maciejczyk A, Pudelko M, Ciesla S, Breborowicz J, Murawa P, Zabel M, Dietel M, Lage H (2007) Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor.
Bulky mediastinal lymphadenopathy at diagnosis is an unfavourable prognostic factor in patients with HL and can be quantified by measuring using the mediastinal mass ratio.
Our findings suggest that high PSMB7 expression is an unfavourable prognostic marker in breast cancer.
High PSMB7 expression is an unfavourable prognostic marker in breast cancer.
Furthermore, low GalNAc-T3 expression of NSCLCs was associated with a shorter survival period, and was an unfavourable prognostic factor.
